- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01531803
Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients
A Prospective, Randomized, Multicenter, Controlled, Open-Label Study to Evaluate the Safety of Kedbumin25% Compared to Normal Saline Solution in the Treatm. of PostSurgical Hypovolemia in Pediatric Patients Undergoing Major Elective Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This randomized, controlled, open-label clinical trial will be conducted at approximately 5 surgical and pediatric intensive care units in the US, over a period of 19 months, with 3 months for trial set-up, 12 months of simultaneous subject enrollment and 30 days of treatment/follow-up period, and 3 months for study close-out.
The study population will consist of at least 60 male and female pediatric subjects between 0 days and 12 years of age, undergoing cardiac, abdominal, orthopedic or transplant surgery with an approximately equal number of subjects (n=10 to 25) in three of the four age groups: (29 days to 23 months), (2 to 5 years 11 months) and (6 years to 12 years) cohorts. Regarding the youngest age group of 0 to 28 days, the minimum number of patients to be enrolled in the study will not be predefined as very a small number of elective surgical procedures is expected in this population.
Safety concerns and eventual safety signals, as well as recruitment rate, will be monitored annually (starting from the enrollment of the 60th subject) by an independent Safety Monitoring Board (SMB), which will be appointed prior to study initiation and submitted to the FDA. The responsibilities of the SMB will be defined in ad hoc document, in which the threshold for acceptable safety will also be set. During the conduct of the study on the first 60 patients, if there is any safety signal linked to the primary safety endpoint (i.e. pulmonary fluid overload) or imbalance in the incidence of AEs between the treatment and control groups or based on relevant literature, as judged by the SMB, the enrolment will be increased to 100 patients using the same age stratification approach defined above (n=20 to 30 in each age group).
Potential subjects will be pre-screened and informed consent/assent will be obtained from the subject and/or subject's parents or guardians prior to surgery. Post-surgery, the subject will be admitted to the Surgical, Neonatal, or Pediatric Intensive Care Unit (SICU/NICU/PICU) for post-operative recovery and care management. Subjects who show signs of hypovolemia as judged by the Principal Investigator (PI) will be screened to determine their eligibility to participate in this trial. Subjects will then be randomized to receive treatment with Kedbumin 25% or the comparator, normal saline (sodium chloride 0.9%).
There is no specific post-treatment regimen for this protocol, as all subjects will receive the standard post-operative care based on their clinical status and response to treatment at the discretion of the Investigator.
Vital signs and fluid management/replacement therapy recorded in the medical chart and results of standard complete blood count (CBC), biochemistry, and hematology and coagulation lab panels will be reviewed and recorded by research staff at specified time points, according to the hospital standard of care. Additionally, research staff will review and record daily lactate, urine albumin, blood urea nitrogen (BUN), creatinine, and non-invasive measurements at the following time points: Baseline, 6hr, 12hr, 24hr, 36hr, 48hr, and 72hr post-onset of hypovolemia), until hemodynamic stability is achieved. Hemodynamic stability will be evaluated based on site-specific age-defined reference ranges for heart rate, blood pressure, urine output, and cardiac index in children.
The volume, rate and frequency of the Investigational Medicinal Product (IMP, either Kedbumin 25% or normal saline) administered will be recorded in addition to the type, timing, and amount of all other fluids administered. The time to hemodynamic stability, duration of stability once attained, and any relapse requiring additional treatment or use of secondary resuscitation strategies will be recorded.
Subjects who demonstrate hemodynamic stability within 3 days after treatment initiation and then relapse into hemodynamic instability as a result of surgical complications or infection will exit from the study, but the data be considered for the safety analysis. These subjects should continue treatment according the clinical practice standard since the study is not intended to evaluate the efficacy of Kedbumin 25%.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Kosair Charities Pediatric Unit
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College Of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Male or female aged 0 days to 12 years, inclusive:
- (0 to 28 days);
- (29 days to 23 months);
- (2 to 5 years 11 months);
- (6 to 12 years).
- Subjects undergoing elective cardiac, abdominal, orthopedic, or transplant surgery.
- Subjects with a clinical diagnosis of hypovolemia developed within 24 hours from the completion of surgery, as judged by the Investigator.
- Admitted to ICU or acute care floor for post-operative recovery and care, in relatively stable condition.
- Subject, parent or guardian agrees to comply with the requirements of the protocol.
- Subject, parent or guardian has signed an informed consent form (ICF) and a child assent form if appropriate.
- Subject, parent or guardian has signed the Health Insurance Portability and Accountability Act (HIPAA) authorization.
Exclusion Criteria:
- Intra-operative blood loss > 50 mL/kg.
- Severe hypoalbuminemia with serum albumin levels < 1g/dL.
- Known intolerance or allergy to albumin and/or plasma proteins.
- Preterm neonates, defined as neonates with a gestational age of <37 weeks (this criteria would only affect the 0-28 days group).
- Burn and trauma patients.
- Renal surgery.
- Subjects with acute CNS injury or trauma would be excluded from the study.
- Chronic renal insufficiency or acute renal failure (creatinine > 1.5 of normal value or based on age-appropriate renal function parameters), or a history of renal transplantation.
- Subjects with hypernatremia, defined as a Na level of ≥ 155 mEq/L.
- Severe congestive heart failure (CHF) using one of the following classification systems: Ross Heart Failure Classification, modified Ross Heart Failure Classification, or New York University Pediatric Heart Failure Index (NYU PHFI).
- Any concurrent medical, surgical or psychiatric condition that may, in the Investigator's opinion, affect the subject's ability to meet the protocol requirements.
- Subject has participated in another interventional clinical study within 30 days prior to study enrollment. Subjects who are participating in another observational study are not excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Kedbumin 25%
Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g/L human albumin, supplied in 50 mL type II vial (each vial containing 12.5g human albumin). The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin). The duration of treatment is based on the subject's response to treatment until hemodynamic stability is achieved. If hemodynamic stability is not achieved within 72 hours of starting the study treatment, the subject will be withdrawn from the study and will be treated according to standard practice and data collected during the study period will be used for the safety evaluation. |
Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g human albumin /L, supplied in 50 mL type II vial (each vial containing 12.5g human albumin). The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin).
Other Names:
|
Placebo Comparator: Normal Saline Solution
Normal (0.9%) saline solution administered via IV infusions of 10 to 20 mL/kg as appropriate per standard of care based on the subject's clinical status and response to treatment.
|
Normal (0.9%) saline solution administered via IV infusions of 10 to 20 mL/kg as appropriate per standard of care based on the subject's clinical status and response to treatment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence, Severity, and Seriousness of Fluid Overload and Edema (Pulmonary Portal or Systemic) and/or Other Complications Secondary to Fluid Resuscitation With Kedbumin 25% Compared to Normal Saline.
Time Frame: 3 days
|
Criteria for Primary Evaluation:
All the measurements for the assessment of the safety parameters will be collected, reviewed, and recorded by research staff until hemodynamic stability is achieved. |
3 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Resolution of Hypovolemia With Adequate Fluid Resuscitation and Restoration of Hemodynamic Stability After Treatment With Kedbumin 25% Compared to Normal Saline Within 72 Hours.
Time Frame: 3 days
|
The secondary safety parameter of resolution of hypovolemia and adequate fluid resuscitation will be evaluated based on the following indicators:
All the measurements for the assessment of the safety parameters will be collected, reviewed, and recorded by research staff until hemodynamic stability is achieved. |
3 days
|
Incidence, Severity and Seriousness of Expected and Unexpected AEs After Treatment With Kedbumin 25% Compared to Normal Saline.
Time Frame: 30 days
|
The severity, seriousness, and relatedness of AEs to the study drug will be observed on repeated administrations of the study drug. Subjects will be carefully monitored by the SICU/NICU/PICU or acute care floor staff for expected and unexpected AEs which occur from the time of dosing to 30 days post dose. If the subject is discharged prior to 30 days, research staff will collect AEs at follow-up visits and via spontaneous reporting by the subject. |
30 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Mirella Calcinai, MD, Kedrion SpA
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KB058
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypovolemia
-
University of California, DavisCompletedAcute HypovolemiaUnited States
-
B. Braun Melsungen AGCompletedTreatment of Hypovolemia and ShockSpain, Bulgaria, Germany, Italy, United Kingdom
-
Fresenius Kabi JapanCompletedPlasma Volume Substitution (Hypovolemia) Including Massive HemorrhageJapan
-
Karolinska InstitutetDanderyd Hospital; Austin Hospital, Melbourne AustraliaUnknownSepsis | Fluid Therapy | Hypovolemia | Post-operative HypovolemiaAustralia, Sweden
-
Azienda Ospedaliera di PadovaUnknownHypovolemia During Liver Transplantation | Renal Hypoperfusion During Liver TransplantationItaly
-
Fresenius KabiB. Braun Melsungen AG; European Society of Anaesthesiology and Intensive CareCompletedHypovolemia Due to Acute Blood LossGermany, Spain, France, Czechia, South Africa, Belgium, Netherlands
-
Zagazig UniversityNot yet recruitingAnesthesia | Fluid Overload | ERAS | Hypovolemia; Surgical Shock
-
Mustafa BurgacActive, not recruiting
-
Universitair Ziekenhuis BrusselCompleted
-
Seoul National University HospitalCompletedHypovolemiaKorea, Republic of
Clinical Trials on Kedbumin 25%
-
Cartesian TherapeuticsRecruitingMultiple Myeloma | Relapse Multiple MyelomaUnited States, Turkey
-
EMSRecruitingAphthous StomatitisBrazil
-
MC2 TherapeuticsRecruitingEfficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) (Orchid 1)Vulvar Lichen SclerosusDenmark
-
MC2 TherapeuticsRecruitingChronic Kidney Disease-associated PruritusUnited Kingdom
-
Zhejiang Hisun Pharmaceutical Co. Ltd.CompletedPrimary Hypercholesterolemia
-
Sheba Medical CenterTerminated
-
Fortuderm Ltd.UnknownPsoriasis VulgarisIsrael
-
Masimo CorporationCompleted
-
Tel-Aviv Sourasky Medical CenterUnknown
-
University Hospital, AntwerpUnknown